As previously reported, Guggenheim analyst Michael Schmidt raised his price target for Deciphera (DCPH) to $66 from $44 after the company announced top-line results from the Phase 3 INVICTUS study of ripretinib in 4L+ GIST, which he believes "significantly exceeded" investors' expectations and validated his bullish thesis and analyses heading into the binary event. The analyst notes that results included a 6.3 months mPFS readout in a setting with no approved therapies and also compare favorably to competitor data from Blueprint Medicines (BPMC) in similar patients. Together with updated Phase 1 ripretinib data across 2L and 3L GISTs, Schmidt thinks these results read-through positively also for the drug's potential in earlier stage GIST patients. Deciphera's Phase 3 INTRIGUE trial in 2L GIST will complete enrolling in the second quarter of 2020, he adds. The analyst has a Buy rating on Deciphera's shares.